

Fig. 1




Fig. 2





Fig. 3



TR: Trastuzumab; BV: Bevacizumab; CTX: Cetuximab; RTX: Rituximab,
NV: Nivolumab; IPL: Ipilimumab; RAM: Ramucirumab,
BRX: Brentuximab vedotin; IFX: Infliximab; ADL: Adalimumab